EPCAM and neoplasm: The APT-PEG-Au-MMNPs@ELC platform, incorporating gold nanoparticles, mesoporous silica, and EpCAM aptamers, enables pH-responsive drug release and tumor-specific targeting, effectively suppressing tumor growth in vitro and in vivo while reducing systemic toxicity (Fig. 10A) [289].